Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
IART's Cash to Debt is ranked lower than
55% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. IART: 0.11 )
IART' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 0.11

Equity to Asset 0.44
IART's Equity to Asset is ranked higher than
53% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. IART: 0.44 )
IART' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.97
Current: 0.44

0.29
0.97
F-Score: 6
Z-Score: 2.28
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 1.08
IART's Operating margin (%) is ranked higher than
64% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. IART: 1.08 )
IART' s 10-Year Operating margin (%) Range
Min: -129.25   Max: 21.36
Current: 1.08

-129.25
21.36
Net-margin (%) -1.06
IART's Net-margin (%) is ranked higher than
63% of the 387 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. IART: -1.06 )
IART' s 10-Year Net-margin (%) Range
Min: -249.02   Max: 31.32
Current: -1.06

-249.02
31.32
ROE (%) -1.35
IART's ROE (%) is ranked higher than
62% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.61 vs. IART: -1.35 )
IART' s 10-Year ROE (%) Range
Min: -145.98   Max: 14.25
Current: -1.35

-145.98
14.25
ROA (%) -0.60
IART's ROA (%) is ranked higher than
64% of the 397 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. IART: -0.60 )
IART' s 10-Year ROA (%) Range
Min: -130.93   Max: 12.84
Current: -0.6

-130.93
12.84
ROC (Joel Greenblatt) (%) 0.84
IART's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 396 Companies
in the Global Medical Devices industry.

( Industry Median: 11.81 vs. IART: 0.84 )
IART' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -175.59   Max: 50.31
Current: 0.84

-175.59
50.31
Revenue Growth (%) 6.60
IART's Revenue Growth (%) is ranked higher than
78% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. IART: 6.60 )
IART' s 10-Year Revenue Growth (%) Range
Min: -3.2   Max: 55.2
Current: 6.6

-3.2
55.2
EBITDA Growth (%) -31.60
IART's EBITDA Growth (%) is ranked higher than
56% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: -2.10 vs. IART: -31.60 )
IART' s 10-Year EBITDA Growth (%) Range
Min: -37.7   Max: 35.2
Current: -31.6

-37.7
35.2
» IART's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

IART Guru Trades in Q3 2013

Richard Snow 48,430 sh (+23.86%)
Ken Fisher 607,515 sh (+0.18%)
Paul Tudor Jones 10,100 sh (-17.21%)
David Dreman 100,464 sh (-72.05%)
» More
Q4 2013

IART Guru Trades in Q4 2013

Richard Snow 62,095 sh (+28.22%)
Paul Tudor Jones 12,300 sh (+21.78%)
David Dreman 114,901 sh (+14.37%)
Ken Fisher 585,215 sh (-3.67%)
» More
Q1 2014

IART Guru Trades in Q1 2014

Steven Cohen 46,100 sh (New)
Robert Olstein 49,000 sh (New)
Richard Snow 64,675 sh (+4.15%)
David Dreman 118,500 sh (+3.13%)
Ken Fisher 574,215 sh (-1.88%)
Paul Tudor Jones 7,700 sh (-37.4%)
» More
Q2 2014

IART Guru Trades in Q2 2014

Jim Simons 7,530 sh (New)
Richard Snow 97,390 sh (+50.58%)
Robert Olstein 55,000 sh (+12.24%)
David Dreman 115,951 sh (-2.15%)
Ken Fisher 532,225 sh (-7.31%)
Paul Tudor Jones 6,000 sh (-22.08%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2013-09-30 Reduce -72.05%0.3%$36.75 - $42.48 $ 49.2425%100464
David Dreman 2013-03-31 New Buy0.44%$38.97 - $44.11 $ 49.2420%423916
Joel Greenblatt 2012-12-31 Sold Out 0.03%$35.99 - $41.72 $ 49.2428%0
Joel Greenblatt 2012-09-30 New Buy0.03%$35.71 - $42.27 $ 49.2426%10255
Joel Greenblatt 2011-09-30 Sold Out 0.0282%$35.7 - $47.56 $ 49.2419%0
Joel Greenblatt 2011-06-30 Reduce -27.9%0.02%$45.61 - $52.35 $ 49.240%4227
George Soros 2011-06-30 Sold Out $45.61 - $52.35 $ 49.240%0
John Hussman 2011-06-30 Sold Out $45.61 - $52.35 $ 49.240%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.29
IART's P/B is ranked higher than
78% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. IART: 2.29 )
IART' s 10-Year P/B Range
Min: 1.33   Max: 6.04
Current: 2.29

1.33
6.04
P/S 1.69
IART's P/S is ranked higher than
80% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. IART: 1.69 )
IART' s 10-Year P/S Range
Min: 0.88   Max: 6.63
Current: 1.69

0.88
6.63
PFCF 54.42
IART's PFCF is ranked higher than
80% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IART: 54.42 )
IART' s 10-Year PFCF Range
Min: 6.81   Max: 260.42
Current: 54.42

6.81
260.42
EV-to-EBIT 260.79
IART's EV-to-EBIT is ranked higher than
68% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 45.27 vs. IART: 260.79 )
IART' s 10-Year EV-to-EBIT Range
Min: 11.6   Max: 408.8
Current: 260.79

11.6
408.8
Shiller P/E 45.52
IART's Shiller P/E is ranked higher than
86% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. IART: 45.52 )
IART' s 10-Year Shiller P/E Range
Min: 17.75   Max: 415.38
Current: 45.52

17.75
415.38
Current Ratio 4.45
IART's Current Ratio is ranked higher than
84% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. IART: 4.45 )
IART' s 10-Year Current Ratio Range
Min: 0.81   Max: 20.74
Current: 4.45

0.81
20.74
Quick Ratio 2.68
IART's Quick Ratio is ranked higher than
76% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. IART: 2.68 )
IART' s 10-Year Quick Ratio Range
Min: 0.46   Max: 19.26
Current: 2.68

0.46
19.26

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.54
IART's Price/DCF (Projected) is ranked higher than
90% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 123.59 vs. IART: 1.54 )
IART' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 16.94
Current: 1.54

0.69
16.94
Price/Median PS Value 0.89
IART's Price/Median PS Value is ranked higher than
85% of the 420 Companies
in the Global Medical Devices industry.

( Industry Median: 1.17 vs. IART: 0.89 )
IART' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 11.03
Current: 0.89

0.56
11.03
Earnings Yield (Greenblatt) 0.40
IART's Earnings Yield (Greenblatt) is ranked lower than
53% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. IART: 0.40 )
IART' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 8.6
Current: 0.4

0.2
8.6
Forward Rate of Return (Yacktman) -16.61
IART's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.32 vs. IART: -16.61 )
IART' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.1   Max: 29.4
Current: -16.61

-16.1
29.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IL3.Germany
Integra LifeSciences Holdings Corporation is a Delaware corporation, incorporated in 1989. The Company was founded on a technology platform to repair and regenerate tissue with engineered collagen devices. The Company is a producer of medical devices for surgeons through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Its products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company has produced product lines for applications ranging from burn and deep tissue wounds to regeneration of dura mater in the brain and repair of nerve and tendon. The Company operates in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The extremity reconstruction refers to the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee (Lower Extremity), and the hand, wrist, elbow and shoulder (Upper Extremity). The U.S. Instruments business is among the largest surgical instrument suppliers in the United States. The U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as a broad and deferential offering of related orthobiologics. The International segment sells similar products to those discussed above, but they are managed through the following geographies: (i) Europe, Middle East and Africa, and (ii) Central/South America, Asia-Pacific and Canada. As a manufacturer and marketer of medical devices, the Company is subject to extensive regulation by the Food and Drug Administrations ("FDA") and the Center for Medicare Services of the U.S. Department of Health and Human Services and other federal governmental agencies and, in some jurisdictions, by state and foreign governmental authorities.
» More Articles for IART

Headlines

Articles On GuruFocus.com
WEEKLY CFO SELLS HIGHLIGHT: LMT, WCG, GRPN, IART, CNK Aug 26 2013 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 10,0 Mar 09 2011 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 125,100 Shares Mar 08 2011 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 5,32 Dec 08 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Dec 03 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Nov 04 2010 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 100, Nov 04 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Oct 28 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Jul 29 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) May 03 2010 

More From Other Websites
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Other Events Sep 08 2014
Integra LifeSciences Announces Changes Within Its Orthopedics and Tissue Technologies Business Sep 02 2014
Integra LifeSciences to Participate in the Morgan Stanley Global Healthcare Conference in September Aug 21 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 19 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Other Events Aug 12 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Financials Aug 12 2014
Integra Lifesciences Holdings Corp Stock Upgraded (IART) Aug 08 2014
Integra LifeSciences Tops Q2 Earnings, Revenues, Shares Up Aug 07 2014
Q2 2014 Integra LifeSciences Corporation Earnings Release - Before Market Open Aug 05 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 10-Q, Quarterly Report Aug 05 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Results of Operations and Financial... Aug 05 2014
Integra LifeSciences Reports Second Quarter 2014 Financial Results Aug 05 2014
Integra LifeSciences Announces Completion of Its Multicenter Clinical Trial for the Treatment of... Aug 05 2014
Christopher Clark, the CFO of Neovasc Inc. (NVCN), Interviews with The Wall Street Transcript Aug 01 2014
Integra LifeSciences to Host Its Second Quarter 2014 Earnings Results Conference Call on August 5,... Jul 10 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 09 2014
Integra LifeSciences Announces Renewal and Extension of Credit Facility Jul 09 2014
Integra Upbeat on DuraSeal Acquisition despite Tepid Q1 Jul 07 2014
Integra Lifesciences Down to Sell Jun 30 2014
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK